Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone

Vaccine

Volumn 33, Issue 35, 2015, Pages 4221-4227

  Medina, Julie ^a,b   Boukhebza, Houda ^a   De Saint Jean, Amélie ^a,c   Sodoyer, Régis ^a,d   Legastelois, Isabelle ^a   Moste, Catherine ^a  

^a SANOFI PASTEUR   (France)

^b GENEURO SA   (Switzerland)

^c UNIVERSITÉ JEAN MONNET   (France)

^d BIOASTER   (France)

Author keywords

Chimeric; Influenza; PR8 backbone; Vaccine

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; SIALIDASE; HYBRID PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIGEN;

2009 H1N1 INFLUENZA; AMNION FLUID; ANIMAL CELL; ARTICLE; CHIMERA; CHO CELL LINE; CONTROLLED STUDY; FEMALE; GENETIC REASSORTMENT; HEMAGGLUTINATION INHIBITION; IMMUNODIFFUSION; INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); NONHUMAN; PRIORITY JOURNAL; REVERSE GENETICS; VACCINE PRODUCTION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; CHLOROCEBUS AETHIOPS; DNA SEQUENCE; DOG; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); MDCK CELL LINE; MOLECULAR GENETICS; PROCEDURES; SEQUENCE ALIGNMENT; VERO CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, VIRAL; CERCOPITHECUS AETHIOPS; DOGS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MADIN DARBY CANINE KIDNEY CELLS; MOLECULAR SEQUENCE DATA; NEURAMINIDASE; REASSORTANT VIRUSES; RECOMBINANT FUSION PROTEINS; REVERSE GENETICS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; VERO CELLS;

EID: 84939573509     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.112     Document Type: Article

References (18)

1. Robertson J.S., Nicolson C., Harvey R., Johnson R., Major D., Guilfoyle K., et al. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 2011, 29:1836-1843.
2. Jing X., Phy K., Li X., Ye Z. Increased hemagglutinin content in a reassortant 2009 pandemic H1N1 influenza virus with chimeric neuraminidase containing donor A/Puerto Rico/8/34 virus transmembrane and stalk domains. Vaccine 2012, 30:4144-4152.
3. Harvey R., Guilfoyle K.A., Roseby S., Robertson J.S., Engelhardt O.G. Improved antigen yield in pandemic H1N1 (2009) candidate vaccine viruses with chimeric hemagglutinin molecules. J Virol 2011, 85:6086-6090.
4. Harvey R., Nicolson C., Johnson R.E., Guilfoyle K.A., Major D.L., Robertson J.S., et al. Improved haemagglutinin antigen content in H5N1 candidate vaccine viruses with chimeric haemagglutinin molecules. Vaccine 2010, 28:8008-8014.
5. Adamo J.E., Liu T., Schmeisser F., Ye Z. Optimizing viral protein yield of influenza virus strain A/Vietnam/1203/2004 by modification of the neuraminidase gene. J Virol 2009, 83:4023-4029.
6. Fournier E., Moules V., Essere B., Paillart J.C., Sirbat J.D., Isel C., et al. A supramolecular assembly formed by influenza A virus genomic RNA segments. Nucl Acids Res 2012, 40:2197-2209.
7. Medina J., Guillot V., Totain E., Rouleau M., Sodoyer R., Moste C., et al. Vero/CHOK1, a novel mixture of cell lines that is optimal for the rescue of influenza A vaccine seeds. J Virol Methods 2014, 196:25-31.
8. Legastelois I., Chevalier M., Bernard M.C., de Montfort A., Fouque M., Pilloud A., et al. Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in egg-derived influenza vaccines. J Virol Methods 2011, 178:129-136.
9. Legastelois I., Garcia-Sastre A., Palese P., Tumpey T.M., Maines T.R., Katz J.M., et al. Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells. Influenza Other Respir Viruses 2007, 1:95-104.
10. Zhou J.J., Tian J., Fang D.Y., Liang Y., Yan H.J., Zhou J.M., et al. Analysis of antigen epitopes and molecular pathogenic characteristics of the 2009 H1N1 pandemic influenza A virus in China. Acta Virol 2011, 55:195-202.
11. European Medicines Agency L, UK Meeting Report - Joint EMA/EDQM workshop on improved potency assays for inactivated influenza vaccines, 12 December 2011 2011, European Medicines Agency L, United Kingdom.
12. Larbaigt G., Gibelin N., Montagnon B., Fanget B., Zayet J. Contribution to the control of inactivated human influenza vaccines with the single radial diffusion method (SRD): routine check, industrial supervision and vaccine standardisation. Comp Immunol Microbiol Infect Dis 1980, 3:207-218.
13. Wanitchang A., Kramyu J., Jongkaewwattana A. Enhancement of reverse genetics-derived swine-origin H1N1 influenza virus seed vaccine growth by inclusion of indigenous polymerase PB1 protein. Virus Res 2010, 147:145-148.
14. Wagner R., Matrosovich M., Klenk H.D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 2002, 12:159-166.
15. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273.
16. Wang T.T., Palese P. Universal epitopes of influenza virus hemagglutinins?. Nat Struct Mol Biol 2009, 16:233-234.
17. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333:850-856.
18. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.